{"schema_version":"secwatch.filing_event.v1","accession":"0000318154-22-000005","form_type":"8-K","ticker":"AMGN","cik":"0000318154","company_name":"AMGEN INC","filed_at":"2022-02-07T23:59:59+00:00","discovered_at":"2026-05-14T18:04:09.224100+00:00","generated_at":"2026-06-27T10:50:52.473465+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Amgen Q4 non-GAAP EPS $4.36, up 26% YoY; full-year revenue $26.0B (+2%)","bullets":["Q4 total revenues $6.8B (+3% YoY); product sales -1% but volumes up for Prolia, Repatha, MVASI, EVENITY.","GAAP EPS $3.36 (+22% Q4); full-year GAAP EPS $10.28 (-16%) due to $1.5B Five Prime IPR&D write-off.","Non-GAAP EPS $4.36 Q4 (+26%), full-year $17.10 (+6%); non-GAAP operating margin 51.1%.","Full-year free cash flow $8.4B, down from $9.9B due to 2020 swap monetization and capex timing.","Quarterly dividend raised to $1.76/share, up 10% YoY (full-year $7.04, +10%)."],"urls":{"canonical":"https://secwatch.observer/filing/0000318154-22-000005","json":"https://secwatch.observer/filing/0000318154-22-000005.json","markdown":"https://secwatch.observer/filing/0000318154-22-000005.md","text":"https://secwatch.observer/filing/0000318154-22-000005.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/318154/000031815422000005/0000318154-22-000005-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/318154/000031815422000005/amgn-20220207.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T10:50:52.473465+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}